Cambridge, MA – Cambridge, Mass. — June 4, 2026 — Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, is proud to announce that its Founder and CEO, Alex Zhavoronkov, has been named to the inaugural SCW75 list by Scientific Computing World . The SCW75 is a new recognition program celebrating the 75 most influential figures driving the transformation of high-performance computing (HPC), AI infrastructure, laboratory informatics, and simulation across the globe.
The launch of the SCW75 comes during a period of unprecedented investment in scientific computing. According to Intersect360 Research, the worldwide market for accelerated and high-performance infrastructure serving AI workloads reached $193 billion in 2024, representing a 121% year-on-year growth. Furthermore, Hyperion Research projects that the broader HPC, AI, and technical computing market will exceed $100 billion by 2028. Zhavoronkov’s recognition among this elite global group highlights his unwavering commitment to applying advanced computational approaches to solve the most difficult problems in biology and chemistry.
From Semiconductors to Extending Human Lifespan
Zhavoronkov's focus on aging and age-related disease is rooted in both personal conviction and strategic foresight. After building a career in the GPU industry in the early 2000s and achieving financial success in semiconductors, he made the decisive choice to pivot away from computing hardware. Instead, he dedicated his resources and expertise to biotechnology with the explicit mission of extending healthy, productive human lifespans.
Under his leadership, Insilico Medicine has pioneered a dual approach to longevity: addressing immediate, age-related diseases by targeting pathways that are implicated in both specific conditions and general aging progression. While the ultimate mission remains "solving aging," this methodology ensures the delivery of near-term therapeutic benefits.
Despite his success with digital prediction models, Zhavoronkov emphasizes that bridging the gap between digital simulation and real-world biology is the defining challenge of modern scientific computing in healthcare. He notes that the central hurdle remains the rigorous experimental validation of computational predictions in animal and human biological systems. He actively encourages early-career researchers to draw motivation from the human impact of their work, such as spending time with patients facing life-threatening illnesses, while maintaining the intense discipline required for progress. "If you are not a genius, you need to work smarter – but also harder than everyone else," advises Zhavoronkov.
Unprecedented Pipeline Scale and Cross-Industry Impact At the core of Insilico's operations is the Pharma.AI platform, an integrated suite comprised of Biology42 for target discovery, Chemistry42 for molecular design, and Medicine42 for clinical insight. By leveraging machine learning and large-scale data analysis, the company has drastically compressed traditional drug discovery timelines that historically took years or decades.
Today, Insilico has rapidly progressed 30 developmental candidates, with 13 advancing to the clinical stage, including multiple Phase I and Phase II trials. Looking ahead, Zhavoronkov has set ambitious milestones: over the next two to three years, Insilico aims to nominate 40 to 50 preclinical candidates and complete the industry's first Phase III clinical trial for a therapeutic discovered utilizing AI.
Beyond human healthcare, Zhavoronkov's vision for scientific computing extends to global sustainability. Through major partnerships, including collaborations with Aramco, Insilico Medicine is deploying its molecular design capabilities to tackle environmental challenges, such as carbon capture, hydrogen storage, and the development of clean synthetic fuels.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK .
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com .
--------------------------------------------------------------------------------
Key Entities & Technologies:
Company: Insilico Medicine (Hong Kong Stock Exchange ticker: 03696.HK).
Leadership: Alex Zhavoronkov, PhD, Founder and CEO.
Core Technology Platform: Pharma.AI.
AI Platform Architecture: The suite includes Biology42 (target discovery), Chemistry42 (molecular design), and Medicine42 (clinical insight).
Methodology: Integration of machine-learning, large-scale data analysis, automated target discovery, and computational modeling to compress traditional drug discovery timelines.
Academic Publications, Citations & Verifiable Research:
Principal Investigator / Author: Alex Zhavoronkov.
Google Scholar Profile: https://scholar.google.com/citations?hl=en&user=8Icccp0AAAAJ&view_op=list_works.
Total Citations: 24,559 citations, h-index: 76, i10-index: 218.
Recent Peer-Reviewed High-Impact Literature:
Pipeline & Clinical Milestones Data:
Lead Candidate: Rentosertib (ISM001-055), a first-in-class small molecule targeting TNIK for Idiopathic Pulmonary Fibrosis (IPF).
Total Developmental Candidates: 30 (since 2021).
Clinical Stage Assets: 13 (including multiple Phase I and Phase II trials).
Future Milestones (24-36 Months): 40-50 preclinical candidates; successful completion of Phase III trials for an AI-discovered therapeutic.
Therapeutic Focus Areas: Fibrosis, Oncology, Immunology, Pain, Obesity, Metabolic Disorders, Ageing, and Age-related diseases.
Cross-Industry Sustainability Applications:
Partnerships: Aramco
Advanced Materials & Sustainability Use Cases: Carbon capture, hydrogen storage, clean synthetic fuels, agriculture, nutritional products, and veterinary medicine.